Schizophrenia Research
Volume 89, Issue 1 , Pages 129-139, January 2007

Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates☆

  • Robin Emsley

      Affiliations

    • University of Stellenbosch, Tygerberg, Cape Town, South Africa
    • ,
  • Jonathan Rabinowitz

      Affiliations

    • Bar Ilan University, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 9 748 3679; fax: +972 9 740 1318.
    • ,
  • Rossella Medori

      Affiliations

    • Janssen-Cilag EMEA, Beerse, Belgium
    • ,
  • Early Psychosis Global Working Group

Received 23 June 2006; received in revised form 12 September 2006; accepted 12 September 2006. published online 10 November 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The randomized controlled drug trial presented in this paper was funded by Johnson and Johnson Pharmaceutical Research and Development. The study included the following investigators and locations: Australia - P. McGorry (Melbourne); T. Lambert (Bentley); J. Kulkarni (Dandenong); Austria - W. Fleischhacker (Innsbruck); Canada - D. Addington (Calgary); L. Kopala (Halifax); R. Williams (Calgary); G. Chouinard (Montreal); A. Labelle (Ottawa); A. Malla (London); S. Purdon (Edmonton); M. Saxena (Hamilton); V. Nair (Montreal); R. Matte (Sherbrooke); S. Johnson (St. John's); L. Beauclair (Montreal); Finland - K. Lehtinen (Tampere); France - E.R. Lombertie (Limoges); J-A. Meynard (La Rochelle); Germany - H. Freyberger (Stralsund); H-J. Möller (Munich); Israel - A. Caspi; M. Davidson (Ramat-Gan); A. Elitzur (Bat-Yam); M. Kotler (Beer Sheva); I. Treves (Hod-Hasharon); A. Weizman (Petach-Tikva); Netherlands - P. Dries (Portugal); New Zealand - D. Codyre (Auckland); South Africa - R. Emsley (Cape Town); C. Gagiano (Bloemfontein); United Kingdom - M. Reveley (Leicester); T. Sharma (London); United States of America - J. Csernansky (St. Louis); L. DeLisi (Stony Brook); J. Lauriello (Albuquerque); T. Manschreck (Fall River); J. Pahl (Oklahoma City); N. Schooler, M. Keshavan (Pittsburgh); S. Schulz (Cleveland); S. Targum (Philadelphia); S. Risch (Charleston).

PII: S0920-9964(06)00405-1

doi:10.1016/j.schres.2006.09.013

Schizophrenia Research
Volume 89, Issue 1 , Pages 129-139, January 2007

Article Tools

* Image Usage & Resolution